- The Alzheimer's Association International Conference begins Monday and runs through July 30 both in person in Denver and online.
- As always, there are several eagerly awaited presentations from companies working on Alzheimer's therapies that could lead to major stock swings.
- This year's conference comes less than two months after the FDA approval of the first Alzheimer's disease-modifying therapy, Biogen's (NASDAQ:BIIB) Aduhelm (aducanumab).
- Here's a look at companies and drug candidates that should be on investors' radar next week.
Eisai
- Biogen's partner on Aduhelm, Eisai (OTCPK:ESALF), is scheduled to make 11 presentations at the conference. The one likely to garner the most attention is on the amyloid-beta targeting antibody lecanemab.
- The company will present a preliminary assessment of phase 2b data following 18 months of treatment with lecanemab in early Alzheimer's.
- Preliminary screening and baseline characteristics for a phase 3 study in preclinical Alzheimer's will also be released.
- Eisai (OTCPK:ESALY) will also make a presentation on the design of a study of the anti-tau antibody E2814.
Cassava Sciences
- July 29 could be a very big day for Cassava Sciences (NASDAQ:SAVA) as it presents an interim analysis of simufilam in a phase 2 trial of 50 patients after nine months of treatment.
- The presentation will include cognition and safety data.
- The company will also have a poster on SavaDx, a plasma biomarker to detect Alzheimer's.
Biogen
- Biogen will make several data presentations on Aduhelm.
- However, a late-breaking presentation on the the design of the real-world, phase 4 study the company will conduct to assess the drug's long-term efficacy may be the most anticipated.
- As a condition of Aduhelm's approval, the FDA required the post-marketing study, which must be submitted within nine years.
- Biogen will also present a poster featuring results from a phase 1b study of BIIB020, an antisense oligonucleotide targeting Tau mRNA in mild Alzheimer's. Biogen is partnered with Ionis Pharmaceuticals (IONS) on the candidate.
- In addition, the company will present a poster on baseline biomarker (Tau PET) characteristics from a phase 2 trial of gosuranemab (BIIB092) in early Alzheimer’s.
AB Science
- French drugmaker AB Science S.A. (OTCPK:ABSCF) will present an abstract on the phase 3 AB09004 study of oral masatinib in mild to moderate Alzheimer's.
- In December, the company released positive phase 2b/3 data on the candidate.
- Shares of AB Science are up nearly 79% over the last year.
Annovis Bio
- Annovis Bio (ANVS) will present new efficacy and biomarker data from an interim analysis of ongoing phase 2a trials for ANVS401.
- Separate data released last month found that ANVS401 can protect some nerve cells from death by infection.
Cortexyme
- Cortexyme (CRTX) will present an update from its pivotal phase 2/3 GAIN trial of atuzaginstat (COR388).
- A partial clinical hold was placed on atuzaginistat by the FDA in February after a review of hepatitic adverse events in the gain trial.
Alector
- Alector (NASDAQ:ALEC) will present two posters on AL002. One will be results of a phase 1 study in healthy volunteers and the other will discuss the study design of the ongoing phase 2 INVOKE-2 trial in early Alzheimer's.
- Alector is partnered with Abbvie (ABBV) on AL002.
- Six- and 12-month data from the company's open-label phase 2 INFRONT-2 study evaluating AL001 in individuals with frontotemporal dementia due to a progranulin gene mutation ("FTD-GRN") will also be presented.
- Dosing in the INVOKE-2 trial began in January.
Longeveron
- An abstract on Longeveron's (LGVN) phase 1 trial of Lomecel-B with mild Alzheimer’s was accepted for a poster presentation.
- The company released positive results on the trial in April.